Aditxt (NASDAQ:ADTX) is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt’s approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.
The company’s product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols. In parallel, Aditxt is advancing a pipeline of peptide-based formulations intended for topical applications such as wound care and surface decontamination. Its research and development activities are conducted at its laboratory facilities in North Brunswick, New Jersey, with additional collaborations in Europe and Latin America under strategic licensing agreements.
Aditxt holds multiple issued and pending patents covering peptide sequences and delivery methods, and the company has established partnerships with academic institutions and contract research organizations to support preclinical and clinical studies. By integrating microbial testing services with the development of proprietary antimicrobial compounds, Aditxt seeks to offer end-to-end solutions that span detection, prevention and treatment of pathogenic microorganisms in diverse settings.
Headquartered in North Brunswick, New Jersey, Aditxt is led by Chief Executive Officer Rami Sinai, who brings experience in biotechnology entrepreneurship and strategic development. The management team combines expertise in peptide chemistry, microbiology and regulatory affairs, positioning the company to advance its technology platforms toward commercialization and to address the global challenge of antimicrobial resistance.
